Security
NewAmsterdam Pharma Company N.V. Warrant · NAMSW
NAMSWNASDAQWarrantCurrentCIK 1936258Updated Oct 6, 2026
Name history
NewAmsterdam Pharma Co B.V. · through Nov 22, 2022
NAMSW price & chart
Loading TradingView…
NASDAQ:NAMSW on TradingView ↗About the company
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company dedicated to building a new standard of care for people living with cardiometabolic and neurodegenerative diseases. The Company is advancing therapies designed to address a significant unmet need for safe, well-tolerated, and convenient treatment options that lower LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in patients at risk of cardiovascular disease with elevated LDL-C. Guided by its mission, the Company challenges convention with courage, translates deep biological insight into meaningful patient impact, and delivers with rigor, precision, and purpose.
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01, 9.01
SCHEDULE 13D/A - filed by Frazier Life Sciences X, L.P. regarding NewAmsterdam Pharma Co N.V.
Other Events
Items 8.01
4 filing
4 filing
Show 5 more recent filings
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 769,284,000Source | 864,620,000Source | 347,097,000Source | 531,583,000Source |
| Property, Plant and Equipment, NetUSD | 383,000Source | 242,000Source | 46,000Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 490,002,000Source | 771,743,000Source | — | — |
| Assets, CurrentUSD | 675,700,000Source | 863,413,000Source | 346,791,000Source | — |
| Prepaid Expense and Other Assets, CurrentUSD | 38,138,000Source | 24,272,000Source | 6,341,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 185,000Source | 431,000Source | 55,000Source | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 85,853,000Source | 107,120,000Source | 58,704,000Source | — |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 14,278,000Source | 13,444,000Source | 10,173,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -762,390,000Source | -558,571,000Source | -316,973,000Source | — |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 4,793,000Source | 4,467,000Source | 4,422,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 683,431,000Source | 757,500,000Source | 288,393,000Source | — |
| Additional Paid in Capital, Common StockUSD | 1,426,750,000Source | 1,298,160,000Source | 590,771,000Source | — |
| Liabilities and EquityUSD | 769,284,000Source | 864,620,000Source | 347,097,000Source | — |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 85,787,000Source | 106,918,000Source | 49,897,000Source | — |
| Operating Lease, Liability, CurrentUSD | 136,000Source | 246,000Source | 60,000Source | — |
| Accounts Payable, CurrentUSD | 8,970,000Source | 4,744,000Source | 16,923,000Source | — |
| Operating Lease, Liability, NoncurrentUSD | 66,000Source | 202,000Source | — | — |
| Additional Financial Items | ||||
| Deferred Revenue, CurrentUSD | 3,987,000Source | 6,008,000Source | 8,942,000Source | — |
| Deferred Revenue, NoncurrentUSD | — | — | 1,019,000Source | — |
| DeferredTaxAssetsUSD | — | — | — | 0Source |
| IntangibleAssetsOtherThanGoodwillEUR | — | — | — | 83,160,000Source |
| IssuedCapitalEUR | — | — | — | 599,191,000Source |
| RentDeferredIncomeClassifiedAsCurrentEUR | — | — | — | 13,008,000Source |
| TradeAndOtherCurrentPayablesEUR | — | — | — | 18,503,000Source |
| TradeAndOtherPayablesEUR | — | — | — | 16,568,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -203,819,000Source | -241,598,000Source | -176,937,000Source | -78,052,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 220,000Source | 113,000Source | 49,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 59,425,000Source | 33,619,000Source | 24,572,000Source | — |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 4,909,000Source | -12,948,000Source | 5,070,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -147,783,000Source | -158,564,000Source | -141,218,000Source | — |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -174,916,000Source | -62,848,000Source | -24,000Source | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | 989,000Source | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 29,520,000Source | 659,507,000Source | 8,912,000Source | — |
| Additional Financial Items | ||||
| AdjustmentsForSharebasedPaymentsEUR | — | — | — | 3,922,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsEUR | — | — | — | 9,256,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 59,425,000Source | 33,619,000Source | 24,572,000Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | -1,405,000Source | -227,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 13,055,000Source | -6,598,000Source | 5,058,000Source | — |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | -12,000Source | — | — | — |
| General and Administrative ExpenseUSD | 15,374,000Source | 14,438,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | -1,000Source | 27,000Source | — |
| InterestPaidClassifiedAsFinancingActivitiesEUR | — | — | — | 9,000Source |
| InterestPaidClassifiedAsOperatingActivitiesEUR | — | — | — | 262,000Source |
| Investment Income, InterestUSD | 27,592,000Source | 16,881,000Source | 11,283,000Source | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | 0Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -203,819,000Source | -241,598,000Source | -176,937,000Source | — |
| Operating ExpensesUSD | 248,186,000Source | 221,852,000Source | 197,057,000Source | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesEUR | — | — | — | 65,000Source |
| Proceeds from Stock Options ExercisedUSD | 29,468,000Source | 1,768,000Source | 290,000Source | — |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesEUR | — | — | — | 728,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 22,503,000Source | 45,563,000Source | 14,090,000Source | — |
| Selling, General and Administrative ExpenseUSD | 106,354,000Source | 70,446,000Source | 37,633,000Source | 22,230,000Source |
| Operating Income (Loss)USD | -225,683,000Source | -176,289,000Source | -182,967,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -203,819,000Source | -241,599,000Source | -176,910,000Source | — |
| Income Tax Expense (Benefit)USD | — | -1,000Source | 27,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -203,819,000Source | -241,598,000Source | -176,937,000Source | — |
| Earnings Per Share, BasicUSD per share | -1.72Source | -2.56Source | -2.15Source | — |
| Earnings Per Share, DilutedUSD per share | -1.72Source | -2.56Source | -2.15Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 118,424,231Source | 94,358,067Source | 82,161,956Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 118,424,231Source | 94,358,067Source | 82,161,956Source | — |
| Additional Financial Items | ||||
| BasicEarningsLossPerShareEUR/shares | — | — | — | -1.97Source |
| Current Income Tax Expense (Benefit)USD | — | -1,000Source | 27,000Source | — |
| DepreciationAndAmortisationExpenseEUR | — | — | — | 72,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 478,000Source | 299,000Source | — | — |
| DepreciationRightofuseAssetsEUR | — | — | — | 64,000Source |
| DilutedEarningsLossPerShareEUR/shares | — | — | — | -1.97Source |
| EmployeeBenefitsExpenseEUR | — | — | — | 11,769,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesEUR | — | — | — | 3,922,000Source |
| FinanceCostsEUR | — | — | — | 271,000Source |
| FinanceIncomeEUR | — | — | — | 11,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 13,055,000Source | -6,598,000Source | 5,058,000Source | — |
| General and Administrative ExpenseUSD | 15,374,000Source | 14,438,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -57,803,000Source | -101,367,000Source | -107,555,000Source | — |
| InterestExpenseOnLeaseLiabilitiesEUR | — | — | — | 9,000Source |
| Investment Income, InterestUSD | 27,592,000Source | 16,881,000Source | 11,283,000Source | — |
| Labor and Related ExpenseUSD | 40,788,000Source | 33,391,000Source | — | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | 0Source | 0Source | — | — |
| Operating ExpensesUSD | 248,186,000Source | 221,852,000Source | 197,057,000Source | — |
| PostemploymentBenefitExpenseDefinedContributionPlansEUR | — | — | — | 66,000Source |
| ProfitLossAttributableToOwnersOfParentEUR | — | — | — | -78,052,000Source |
| ProfitLossBeforeTaxEUR | — | — | — | -78,052,000Source |
| ProfitLossFromOperatingActivitiesEUR | — | — | — | -67,560,000Source |
| Research and Development ExpenseUSD | 141,832,000Source | 151,406,000Source | 159,424,000Source | 82,230,000Source |
Filing attachments
nams-ex99_1.htm · 8-K · 2026-09-29
Exhibit 99.1 NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease - SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood-based biomarkers associated with Alzheimer’s disease, including p-tau 217, and additional cognitive and functional measures- Naarden, the Ne…
Read attachment ↗nams-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 nams-ex99_1.htm EX-99.1 EX-99.1 NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe - - PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 - - Topline data from RUBENS Phase 3 expected by year-end 2026 - - $678.3 million in cash, cash equivalents and marketable securities at June 30, 2026 - - Company to…
Read attachment ↗nams-ex99_1.htm · 8-K · 2026-07-24
EX-99.1 2 nams-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - Positive CHMP opinion supports potential commercialization of obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combination in Europe - - Recommendation based on positive Phase 3 BROADWAY, BROOKLYN, and TANDEM data …
Read attachment ↗nams-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 nams-ex99_1.htm EX-99.1 EX-99.1 NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results - Decisions on regulatory approval from EMA, UK, and Switzerland for obicetrapib and obicetrapib/ezetimibe fixed‑dose combination expected in 2H26, and based on the outcomes, with potential launches by Menarini in 4Q26 in Germany and the UK - - PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q2027 - - Completed enrollment in REMBRANDT; T…
Read attachment ↗nams-ex99_1.htm · 8-K · 2026-03-02
EX-99.1 2 nams-ex99_1.htm EX-99.1 Investor Presentation as of March 2, 2026 Nasdaq: NAMS Disclaimers Forward Looking Statements This presentation and the accompanying oral statements made in connection herewith (collectively, this “Presentation”) contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and are subject to the “safe harbor” provisions created thereunder. All statements that are not historical facts are hereby…
Read attachment ↗nams-ex99_1.htm · 8-K · 2026-02-18
EX-99.1 2 nams-ex99_1.htm EX-99.1 EX-99.1 NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update -- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate during the initial 12-months tracking in line with observed event rate in BROADWAY-- -- Topline data from RUBENS Phase 3 trial in patients with type 2 diabetes and metab…
Read attachment ↗